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Summary
Autosomal dominant pure hereditary spastic paraplegia
(ADPHSP) is clinically characterized by slowly progres-
sive lower-limb spasticity. The condition is genetically
heterogeneous, and loci have been mapped at chromo-
somes 2p, 8q, 14q, and 15q. We have performed a ge-
nomewide linkage screen on a large family with
ADPHSP, in which linkage to all four previously known
loci was excluded. Analysis of markers on chromosome
12q gave a peak pairwise LOD score of 3.61 at
D12S1691, allowing us to assign a new locus for
ADPHSP (a locus that we have designated “SPG10”) to
this region. Haplotype construction and analysis of re-
combination events narrowed the SPG10 locus to a 9.2-
cM region between markers D12S368 and D12S83. In
addition, our data strongly suggest that there are at least
six ADPHSP loci, since we describe a further family in
which linkage to all five known ADPHSP loci has been
excluded.
Introduction
The hereditary spastic paraplegias (HSPs) are neurode-
generative disorders whose principal feature is progres-
sive lower-limb spasticity. They are classified as “pure”
when spastic paraplegia exists in isolation and as com-
plicated when other major clinical features are present.
Autosomal dominant, autosomal recessive, and X-
linked–recessive inheritance patterns have been de-
scribed for both pure and complicated forms (Harding
Received April 28, 1999; accepted for publication June 23, 1999;
electronically published July 29, 1999.
Address for correspondence and reprints: Dr. D. C. Rubinsztein,
Department of Medical Genetics, Cambridge Institute for Med-
ical Research, Level 4, Wellcome/MRC Building, Addenbrooke’s Hos-
pital, Hills Road, Cambridge CB2 2XY, United Kingdom. E-mail:
dcr1000@cus.cam.ac.uk
 1999 by The American Society of Human Genetics. All rights reserved.
0002-9297/1999/6503-0022$02.00
1984; Kobayashi et al. 1995; Fink and Heiman-Patter-
son 1996; Reid 1997).
Although patients with autosomal dominant pure he-
reditary spastic paraplegia (ADPHSP) generally have the
same core clinical features—that is, spastic gait abnor-
mality, lower-limb hypertonicity, pyramidal weakness,
hyperreflexia, and extensor-plantar responses—there is
considerable variation in age at onset and severity of
spasticity, both within and between families (Harding
1981; Polo et al. 1993; Du¨rr et al. 1994; De Jonghe et
al. 1996; Nielsen et al. 1998; Reid et al., in press-b). In
addition to locomotor problems, bladder dysfunction
and overt or subclinical sensory abnormalities are com-
mon, and subclinical cognitive impairment may be pre-
sent (Harding 1981; Schady and Sheard 1990; Tedeschi
et al. 1991; Polo et al. 1993; Du¨rr et al. 1994; Webb
and Hutchinson 1998).
There is considerable genetic heterogeneity in
ADPHSP, with loci mapped on chromosomes 2p (SPG4
[MIM 182601]) (Hazan et al. 1994; Hentati et al.
1994b), 8q (SPG8 [MIM 603563–]) (Hedera et al. 1999;
Reid et al., in press-a), 14q (SPG3 [MIM 182600]) (Ha-
zan et al. 1993), and 15q (SPG6 [MIM 600363]) (Fink
et al. 1995). The existence of at least one further
ADPHSP locus is strongly suggested by the exclusion of
linkage at all four of these loci in some families (Reid
et al., in press-a).
In previous studies, we identified a large “unlinked”
family, for which linkage at all known ADPHSP loci was
excluded (Reid et al., in press-a, in press-b). We have
now mapped, using a genomewide screen, the respon-
sible gene in this family, to a 9.2-cM region at chro-
mosome 12q13. Linkage at this locus was excluded in
a second “unlinked” family, strongly suggesting the pres-
ence of at least one further ADPHSP locus.
Subjects and Methods
Clinical Ascertainment
The families included in the present study (families 4
[fig. 1] and 28) were ascertained as part of a United
Kingdom–wide clinical and genetic study of ADPHSP,
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Figure 1 Family tree of ADPHSP family 4, showing haplotypes for markers around SPG10 region. The marker order, from top to bottom,
is D12S345, D12S85, D12S368, D12S1586, D12S1691, D12S83, and D12S326. For clarity, noncontributory haplotypes are represented by a
uniform hatched-shaded pattern. Recombination events in affected individuals narrow the SPG10 critical region to a 9.2-cM region between
D12S368 and D12S83 (Dib et al. 1996). For confidentiality, the sex of the subjects has not been provided.
which has been described elsewhere (Reid et al., in press-
b). Both families have previously been formally excluded
from linkage to the loci on chromosomes 2p, 8q, 14q,
and 15q, with multipoint linkage analysis giving LOD
scores !2, throughout the candidate regions for each
of these loci (Reid et al., in press-a, in press-b). After
informed consent was obtained, all available affected
and apparently unaffected family members were neu-
rologically assessed by a single physician (E.R.), using a
standard protocol. Diagnostic criteria for ADPHSP were
based on those of Harding and have been described else-
where (Harding 1981, 1984; Reid et al., in press-b). In
brief, subjects were classified as being affected if they
had lower-limb hyperreflexia in addition to at least one
of the following: progressive spastic gait abnormality,
bilateral extensor-plantar reflex, and/or bilateral sus-
tained (5 beats) ankle or knee clonus. Subjects were
classified as being possibly affected if lower-limb hyper-
reflexia was present without other abnormal signs, and
they were classified as being normal if the results of
neurological examination were entirely normal. Ethical
approval for the study was granted by the Adden-
brooke’s Hospital ethical committee. In total, 45 family
members from the two families were clinically assessed.
In addition, DNA samples were available from a further
affected subject from family 28, who was a deceased
obligate gene carrier, and from four spouses.
DNA Analysis
A genomewide screen, excluding the X chromosome
(since male-to-male transmission was present), was per-
formed on DNA samples from family 4, by means of
ABI Linkage Mapping Set version 2 (LMS2) (Perkin-
Elmer). This set consists of fluorescently labeled PCR
primer pairs for 400 highly polymorphic dinucleotide-
repeat microsatellite markers chosen from the Ge´ne´thon
human linkage map (Weissenbach et al. 1992; Gyapay
et al. 1994; Dib et al. 1996). The markers have an av-
erage spacing of 10 cM and incorporate reverse-
primer–tailing chemistry (Brownstein et al. 1996). DNA
samples were isolated from blood of all consenting in-
dividuals. PCR reactions were performed for each
marker individually, in a 5-ml reaction volume containing
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∼50 ng of DNA, 2.5 mM MgCl2, 10 mM Tris-HCl pH
8.3, 50 mM KCl, 250 mM each dNTP, 0.625 pmol of
each primer, and 0.25 units of AmpliTaq Gold (Perkin-
Elmer). Reactions were performed on a Perkin-Elmer
9600 thermal cycler or by means of an ABI 877 inte-
grated thermal-cycler robot. A standard thermocycling
profile was used for all markers; it consisted of an initial
denaturation at 95C for 12 min, which was followed
by 10 cycles each of denaturation at 95C for 15 s,
annealing at 55C for 15 s, and synthesis at 72C for
30 s. This was followed by 20 cycles each of denatur-
ation at 89C for 15 s, annealing at 55C for 15 s, and
synthesis at 72C for 30 s and by a final extension step
at 72C for 10 min. PCR products for selected sets of
markers were pooled, ethanol precipitated, and size frac-
tionated on a 5% denaturing polyacrylamide gel (Am-
resco) by electrophoresis on an ABI 377XL sequencer.
PCR products were sized by the Genescan version 2.1
program and were scored by the Genotyper version 2.0
program. In addition to the LMS2marker set, twomark-
ers—D12S1586 and D12S1691—were used in genotyp-
ing. Primer sequences for these additional markers are
available from the Ge´ne´thon microsatellite linkage map
(Dib et al. 1996). PCR reaction and thermocycling con-
ditions were identical to those used for the LMS2marker
set.
Linkage Analysis
Pairwise linkage analysis was performed by the
MLINK program of the FASTLINK version 4.0P pack-
age (Lathrop et al. 1985), accessed via the Genetic Link-
age User Environment interface (UK Human Genome
Mapping Project Resource Centre). Multipoint linkage
analysis was performed with the programLinkmap,with
previously published between-marker genetic distances,
which were calculated by the CILINK program (Dib et
al. 1996). For linkage calculations, allele frequencies
were assumed to be equal, the gene frequency for
ADPHSP was assumed to be 104, and male and female
recombination rates were assumed to be equal.
Statistical Methods
Age-at-onset data were compared by the unpaired t-
test.
Results
Clinical Features
Clinical information on families 4 and 28 has been
presented elsewhere (Reid et al., in press-a, in press-b).
All except a single affected subject in family 4 had a
symptomatic spastic-gait abnormality, in addition to
lower-limb hyperreflexia, meeting the Hereditary Spastic
Paraplegia Working Group diagnostic criteria for being
“definitely affected,” as well as our own diagnostic cri-
teria (Fink and Heiman-Patterson 1996). The asymp-
tomatic patient from family 4 (II:9) was an obligate gene
carrier who had bilateral lower-limb hyperreflexia, bi-
lateral extensor-plantar responses, and unilateral sus-
tained ankle clonus. One previously asymptomatic af-
fected patient from family 4 had become symptomatic
since our earlier descriptions of this family (Reid et al.,
in press-a, in press-b). The age at onset ofmean  SD
symptoms in family 4 was years (range 8–4010.8 9.6
years), and that in family 28 was years (range6.9 6.2
5–22 years). Asymptomatic patients were not included
in age-at-onset calculations.
Identification of a Novel ADPHSP Locus
We performed a genome screen on family 4, a large
family with ADPHSP and in which linkage at all four
previously identified ADPHSP loci has been excluded
(Reid et al., in press-a, in press-b). In view of the age-
dependent penetrance of ADPHSP, pairwise LOD scores
for genome-screen markers were calculated by the con-
servative, affected-only approach. No pairwise LOD
score 13.0 was obtained with the genome-screen mark-
ers. We therefore constructed haplotypes around mark-
ers for which the pairwise LOD score was 10.5. This
allowed us to identify a region, flanked by markers
D12S368 and D12S83 (both of which showed recom-
binations with the disease gene, albeit in different sub-
jects), where complete segregation of the disease with
intervening markers might be possible. Markers
D12S1586 and D12S1691 (Dib et al. 1996), located be-
tween D12S368 and D12S83, were genotyped. Both of
these markers segregated entirely with the disease; pair-
wise LOD scores for these markers, based on affected-
only analysis, are shown in table 1. The peak two-point
LOD score is 3.31 at marker D12S1691. Pairwise LOD
scores were recalculated with the inclusion of genotyping
data from an elderly (age 55 years, 15 years older than
maximum age at onset of disease within family 4) clin-
ically normal subject, who was coded as unaffected. Dis-
ease penetrance was assumed to be 99%, as has been
suggested elsewhere (Hazan et al. 1994) (table 1). The
peak LOD score rose to 3.61 at D12S1691, strongly
supporting the assignment of a new ADPHSP locus
(which we have designated “SPG10”) to this region.
Haplotypes were constructed for markers D12S345,
D12S85, D12S368, D12S1586, D12S1691, D12S83,
and D12S326. Recombination events in affected indi-
viduals place the disease locus within a 9.2-cM interval,
flanked by D12S368 and D12S83 (figs. 1 and 2).
Exclusion Mapping
We went on to examine a further family, family 28,
for linkage to the SPG10 locus. Linkage at the ADPHSP
loci on chromosomes 2p, 8q, 14q, and 15q had previ-
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Table 1
LOD Scores for Families 4 and 28, with Markers from SPG10
Region
FAMILY
AND MARKER
LOD SCORE AT v =
0 .05 .1 .2 .3 .4 .5
Affected-Only Analysis
4:
D12S368  .89 .96 .77 .45 .13 0
D12S1586 2.41 2.16 1.91 1.38 .81 .27 0
D12S1691 3.31 3.02 2.72 2.06 1.33 .56 0
D12S83  .25 .04 .05 .07 .02 0
28:
D12S368  .57 .09 .24 .28 .19 0
D12S1586  .58 .09 .24 .29 .19 0
D12S1691  .30 .16 .45 .44 .28 0
D12S83  .86 .35 .04 .14 .12 0
Analysis with Unaffected Subject Includeda
4:
D12S368  1.16 1.21 0.97 0.58 0.17 0
D12S1586 2.71 2.44 2.17 1.57 0.94 0.31 0
D12S1691 3.61 3.30 2.97 2.26 1.46 0.60 0
D12S83  0.17 0.03 0.13 0.10 0.03 0
a Unaffected individual was 15 years older than oldest age at onset
in the family.
Figure 2 Schematic genetic map showing selected chromosome
12 markers. The SPG10 critical region lies between D12S368 and
D12S83. Previously published genetic distances between markers, cal-
culated by the CILINK program, are shown on the left (Dib et al.
1996).
ously been excluded in this family, by multipoint linkage
analysis giving LOD scores !2 throughout the relevant
candidate regions (Reid et al., in press-a, in press-b).
DNA samples from this family were genotyped with four
markers from the SPG10 critical region. Two-point LOD
scores for these markers, based on affected-only analysis,
are given in table 1. Multipoint analysis was performed,
by affected-only analysis, with markers D12S368,
D12S1691, and D12S83. This generated LOD scores
!2 throughout the SPG10 critical region, formally ex-
cluding linkage at this locus.
Locus-Phenotype Correlations
It has been suggested that age at onset of ADPHSP
correlates with genetic locus (e.g., see Reid et al., in
press-b). In terms of age at onset of symp-mean  SD
toms, there was no significant difference between family
4 ( years) and family 28 ( years;10.8 9.6 6.9 6.2
linkage excluded at all known ADPHSP loci); however,
the age at onset of symptoms in family 4mean  SD
is younger than that (i.e., years) which has29.6 11.0
been reported elsewhere (Reid et al., in press-a) for a
family with linkage to SPG8 ( ). We assessedP = .0001
whether there was any significant age-at-onset difference
between families 4 and 28 and seven U.K. families (fam-
ilies 2, 5, 7, 22, 24, 25, and 27 in the study by Reid et
al. [in press-b]; mean age at onset years) in24.1 12.3
which linkage to the chromosome 2 ADPHSP locus is
likely. Families 4 and 28 both had a significantly younger
mean age at onset than was reported for the pooled
families with linkage to chromosome 2 ( forP = .001
family 4; for family 28).P = .0002
Discussion
Our results confirm the presence of extensive genetic
heterogeneity in ADPHSP. Previously, four loci for
ADPHSP had been identified, on chromosomes 2p, 8q,
14q, and 15q, and had been narrowed to regions of 3
cM, 3.4 cM, 5 cM, and 7 cM, respectively (in a family
with complicated HSP, the phenotype mapped to a 0-
cM interval at the SPG4 locus, but it is possible that the
responsible gene in this family may be different from
that involved in autosomal dominant pureHSP [Heinzlef
et al. 1998]) (Hazan et al. 1993, 1994; Hentati et al.
1994b; Fink et al. 1995; Bu¨rger et al. 1996; Scott et al.
1997; Paternotte et al. 1998; Hedera et al. 1999; Reid
et al., in press-a). We have now identified a fifth locus
for ADPHSP, in a 9.2-cM region between D12S368 and
D12S83, at chromosome 12q13 (Genome Database). In
addition, our results strongly suggest that there are at
least six ADPHSP loci, since we have identified a family
in which linkage to all five known ADPHSP loci has
been excluded.
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Our mapping of the SPG10 locus brings to 10 the
number of genes implicated in HSP that have been
mapped or cloned, including 2 recessive genes and 2 X-
linked genes. Recessive HSP genes map to chromosome
8q (SPG5 [MIM 270800]) and chromosome 16q (SPG7
[MIM 602783]) (Hentati et al. 1994a; De Michelle et
al. 1998). The SPG7 gene has been cloned, and different
mutations in this gene are associated with pure or com-
plicated (by optic, cerebellar, and cortical atrophy) HSP
(Casari et al. 1998). The protein product of this gene,
paraplegin, is a nuclear-encoded mitochondrial metal-
loprotease that also has a chaperone function, and HSP
patients with paraplegin mutations have defects in ox-
idative phosphorylation (Casari et al. 1998). Mutations
in a myelin gene, the proteolipid protein (PLP) gene
(SPG2 [MIM 312900]), at Xq22, are associated with X-
linked pure and complicated HSP (Saugier-Veber et al.
1994; Cambi et al. 1996), whereas a form of X-linked
HSP, in which spasticity is accompanied by mental re-
tardation and adducted thumbs, is caused by mutations
in the neural cell–adhesion molecule L1 (L1-CAM) gene
(SPG1 [MIM 312920], at Xq28 (Jouet et al. 1994). Fi-
nally, a gene (SPG9 [MIM 601162]) causing autosomal
dominant HSP complicated by cataracts, gastroesopha-
geal reflux, and amyotrophy has been mapped to chro-
mosome 10q (Seri et al. 1999).
Correlations between ADPHSP genetic locus and age
at onset of symptoms are likely to exist. Three separate
studies involving a total of 24 families with linkage to
chromosome 2 have found no significant age-at-onset
difference between families (Du¨rr et al. 1996; Nielsen et
al. 1998; Reid et al., in press-b), and, in the two families
with linkage to chromosome 8 and in the single family
with linkage to chromosome 15 that have been identi-
fied, the mean age at onset was similar to that in families
with linkage to chromosome 2 (Fink et al. 1995; Hedera
et al. 1999; Reid et al., in press-a). On the other hand,
families with linkage to chromosome 14 have a consis-
tently early mean age at onset, usually !10 years (Hazan
et al. 1993; Hentati et al. 1994b; Gispert et al. 1995;
Haung et al. 1997; Paternotte et al. 1998), and our data
indicate that chromosome 12-linked ADPHSP may also
have an early age at onset. These apparent correlations
need to be confirmed by further data on families with
linkage to known loci, but they suggest that there are
locus-specific differences in the molecular pathology of
ADPHSP. As in the case of families with HSP mapped
to other loci, there was a wide range in disease severity
within family 4, with some patients requiring a wheel-
chair, whereas one patient was asymptomatic at age 40
years. This intriguing variability suggests that genetic
background or perhaps environmental influences may
modify the disease process.
In summary, the data presented in this study identify
a fifth locus for ADPHSP and strongly suggest that there
are at least six ADPHSP loci. Clarification of the full
extent of genetic heterogeneity in ADPHSP will facilitate
the eventual cloning of ADPHSP genes and also will
allow more-accurate genetic counseling of affected
families.
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